3 Recession-Proof ETFs to Invest in Now
The U.S. gross domestic product (GDP) contracted 0.3% during the…
Buy
58
HLN Quote, Financials, Valuation and Earnings
Last price:
$10.74
Seasonality move
:
4.69%
Day range:
$10.73 - $10.84
52-week range:
$8.22 - $10.85
Dividend yield:
1.58%
P/E ratio:
26.69x
P/S ratio:
3.43x
P/B ratio:
2.39x
Volume:
17.7M
Avg. volume:
15.3M
1-year change:
30.02%
Market cap:
$48.5B
Revenue:
$14.4B
EPS (TTM):
$0.40
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
HLN
Haleon PLC
|
$3.8B | $0.32 | 0.78% | 8.98% | $11.13 |
|
ADAP
Adaptimmune Therapeutics PLC
|
$6.6M | -$0.17 | -92.5% | -8.33% | $1.71 |
|
AZN
AstraZeneca PLC
|
$13.7B | $1.12 | 8.72% | 84.16% | $84.16 |
|
GSK
GSK PLC
|
$10B | $1.04 | 5.98% | 60.08% | $41.59 |
|
PFE
Pfizer
|
$14.1B | $0.67 | 1.01% | 5555.3% | $29.25 |
|
SNN
Smith & Nephew PLC
|
$1.4B | -- | -- | -- | $32.84 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
HLN
Haleon PLC
|
$10.74 | $11.13 | $48.5B | 26.69x | $0.12 | 1.58% | 3.43x |
|
ADAP
Adaptimmune Therapeutics PLC
|
$0.29 | $1.71 | $75.3M | -- | $0.00 | 0% | 0.42x |
|
AZN
AstraZeneca PLC
|
$67.57 | $84.16 | $209.5B | 27.14x | $1.05 | 2.29% | 3.84x |
|
GSK
GSK PLC
|
$36.62 | $41.59 | $74.4B | 18.99x | $0.40 | 4.25% | 1.88x |
|
PFE
Pfizer
|
$22.28 | $29.25 | $126.7B | 16.14x | $0.43 | 7.63% | 2.03x |
|
SNN
Smith & Nephew PLC
|
$28.34 | $32.84 | $12.4B | 30.15x | $0.46 | 2.65% | 2.14x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
HLN
Haleon PLC
|
38.17% | 0.061 | 28.98% | 0.75x |
|
ADAP
Adaptimmune Therapeutics PLC
|
80.92% | 3.631 | 36.44% | 2.60x |
|
AZN
AstraZeneca PLC
|
42.02% | 0.321 | 13.05% | 0.69x |
|
GSK
GSK PLC
|
56.56% | -0.257 | 30.39% | 0.58x |
|
PFE
Pfizer
|
40.42% | 0.423 | 42.46% | 0.88x |
|
SNN
Smith & Nephew PLC
|
37.25% | 0.598 | 29.11% | 1.21x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
HLN
Haleon PLC
|
$2B | $448.1M | 5.64% | 8.91% | 14.46% | $921M |
|
ADAP
Adaptimmune Therapeutics PLC
|
-- | -$57.2M | -93.9% | -140.5% | -2197.67% | -$35.4M |
|
AZN
AstraZeneca PLC
|
$11.3B | $3.7B | 10.93% | 19.55% | 27.61% | $2.7B |
|
GSK
GSK PLC
|
$7B | $2.8B | 10.19% | 23.08% | 30.2% | $877.6M |
|
PFE
Pfizer
|
$10.9B | $4.4B | 5.05% | 8.72% | 25.08% | $1.8B |
|
SNN
Smith & Nephew PLC
|
-- | -- | 4.91% | 7.88% | -- | -- |
Haleon PLC vs. Competitors
-
Which has Higher Returns HLN or ADAP?
Adaptimmune Therapeutics PLC has a net margin of 8.37% compared to Haleon PLC's net margin of -2303.38%. Haleon PLC's return on equity of 8.91% beat Adaptimmune Therapeutics PLC's return on equity of -140.5%.
Company Gross Margin Earnings Per Share Invested Capital HLNHaleon PLC55.38% $0.06 $32.9B ADAPAdaptimmune Therapeutics PLC-- -$0.31 $62.1M -
What do Analysts Say About HLN or ADAP?
Haleon PLC has a consensus price target of $11.13, signalling upside risk potential of 3.66%. On the other hand Adaptimmune Therapeutics PLC has an analysts' consensus of $1.71 which suggests that it could grow by 483.13%. Given that Adaptimmune Therapeutics PLC has higher upside potential than Haleon PLC, analysts believe Adaptimmune Therapeutics PLC is more attractive than Haleon PLC.
Company Buy Ratings Hold Ratings Sell Ratings HLNHaleon PLC2 1 0 ADAPAdaptimmune Therapeutics PLC2 3 0 -
Is HLN or ADAP More Risky?
Haleon PLC has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Adaptimmune Therapeutics PLC has a beta of 2.857, suggesting its more volatile than the S&P 500 by 185.668%.
-
Which is a Better Dividend Stock HLN or ADAP?
Haleon PLC has a quarterly dividend of $0.12 per share corresponding to a yield of 1.58%. Adaptimmune Therapeutics PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Haleon PLC pays 39.53% of its earnings as a dividend. Adaptimmune Therapeutics PLC pays out -- of its earnings as a dividend. Haleon PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios HLN or ADAP?
Haleon PLC quarterly revenues are $3.5B, which are larger than Adaptimmune Therapeutics PLC quarterly revenues of $3.2M. Haleon PLC's net income of $295.8M is higher than Adaptimmune Therapeutics PLC's net income of -$74.2M. Notably, Haleon PLC's price-to-earnings ratio is 26.69x while Adaptimmune Therapeutics PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Haleon PLC is 3.43x versus 0.42x for Adaptimmune Therapeutics PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HLNHaleon PLC3.43x 26.69x $3.5B $295.8M ADAPAdaptimmune Therapeutics PLC0.42x -- $3.2M -$74.2M
-
Which has Higher Returns HLN or AZN?
AstraZeneca PLC has a net margin of 8.37% compared to Haleon PLC's net margin of 21.46%. Haleon PLC's return on equity of 8.91% beat AstraZeneca PLC's return on equity of 19.55%.
Company Gross Margin Earnings Per Share Invested Capital HLNHaleon PLC55.38% $0.06 $32.9B AZNAstraZeneca PLC83.51% $0.94 $70.9B -
What do Analysts Say About HLN or AZN?
Haleon PLC has a consensus price target of $11.13, signalling upside risk potential of 3.66%. On the other hand AstraZeneca PLC has an analysts' consensus of $84.16 which suggests that it could grow by 24.55%. Given that AstraZeneca PLC has higher upside potential than Haleon PLC, analysts believe AstraZeneca PLC is more attractive than Haleon PLC.
Company Buy Ratings Hold Ratings Sell Ratings HLNHaleon PLC2 1 0 AZNAstraZeneca PLC6 1 0 -
Is HLN or AZN More Risky?
Haleon PLC has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison AstraZeneca PLC has a beta of 0.396, suggesting its less volatile than the S&P 500 by 60.428%.
-
Which is a Better Dividend Stock HLN or AZN?
Haleon PLC has a quarterly dividend of $0.12 per share corresponding to a yield of 1.58%. AstraZeneca PLC offers a yield of 2.29% to investors and pays a quarterly dividend of $1.05 per share. Haleon PLC pays 39.53% of its earnings as a dividend. AstraZeneca PLC pays out 65.8% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios HLN or AZN?
Haleon PLC quarterly revenues are $3.5B, which are smaller than AstraZeneca PLC quarterly revenues of $13.6B. Haleon PLC's net income of $295.8M is lower than AstraZeneca PLC's net income of $2.9B. Notably, Haleon PLC's price-to-earnings ratio is 26.69x while AstraZeneca PLC's PE ratio is 27.14x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Haleon PLC is 3.43x versus 3.84x for AstraZeneca PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HLNHaleon PLC3.43x 26.69x $3.5B $295.8M AZNAstraZeneca PLC3.84x 27.14x $13.6B $2.9B
-
Which has Higher Returns HLN or GSK?
GSK PLC has a net margin of 8.37% compared to Haleon PLC's net margin of 21.61%. Haleon PLC's return on equity of 8.91% beat GSK PLC's return on equity of 23.08%.
Company Gross Margin Earnings Per Share Invested Capital HLNHaleon PLC55.38% $0.06 $32.9B GSKGSK PLC74.23% $0.99 $41.5B -
What do Analysts Say About HLN or GSK?
Haleon PLC has a consensus price target of $11.13, signalling upside risk potential of 3.66%. On the other hand GSK PLC has an analysts' consensus of $41.59 which suggests that it could grow by 13.58%. Given that GSK PLC has higher upside potential than Haleon PLC, analysts believe GSK PLC is more attractive than Haleon PLC.
Company Buy Ratings Hold Ratings Sell Ratings HLNHaleon PLC2 1 0 GSKGSK PLC2 4 1 -
Is HLN or GSK More Risky?
Haleon PLC has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison GSK PLC has a beta of 0.539, suggesting its less volatile than the S&P 500 by 46.147%.
-
Which is a Better Dividend Stock HLN or GSK?
Haleon PLC has a quarterly dividend of $0.12 per share corresponding to a yield of 1.58%. GSK PLC offers a yield of 4.25% to investors and pays a quarterly dividend of $0.40 per share. Haleon PLC pays 39.53% of its earnings as a dividend. GSK PLC pays out 94.91% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios HLN or GSK?
Haleon PLC quarterly revenues are $3.5B, which are smaller than GSK PLC quarterly revenues of $9.5B. Haleon PLC's net income of $295.8M is lower than GSK PLC's net income of $2B. Notably, Haleon PLC's price-to-earnings ratio is 26.69x while GSK PLC's PE ratio is 18.99x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Haleon PLC is 3.43x versus 1.88x for GSK PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HLNHaleon PLC3.43x 26.69x $3.5B $295.8M GSKGSK PLC1.88x 18.99x $9.5B $2B
-
Which has Higher Returns HLN or PFE?
Pfizer has a net margin of 8.37% compared to Haleon PLC's net margin of 21.63%. Haleon PLC's return on equity of 8.91% beat Pfizer's return on equity of 8.72%.
Company Gross Margin Earnings Per Share Invested Capital HLNHaleon PLC55.38% $0.06 $32.9B PFEPfizer79.26% $0.52 $151.9B -
What do Analysts Say About HLN or PFE?
Haleon PLC has a consensus price target of $11.13, signalling upside risk potential of 3.66%. On the other hand Pfizer has an analysts' consensus of $29.25 which suggests that it could grow by 31.27%. Given that Pfizer has higher upside potential than Haleon PLC, analysts believe Pfizer is more attractive than Haleon PLC.
Company Buy Ratings Hold Ratings Sell Ratings HLNHaleon PLC2 1 0 PFEPfizer6 15 1 -
Is HLN or PFE More Risky?
Haleon PLC has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Pfizer has a beta of 0.588, suggesting its less volatile than the S&P 500 by 41.208%.
-
Which is a Better Dividend Stock HLN or PFE?
Haleon PLC has a quarterly dividend of $0.12 per share corresponding to a yield of 1.58%. Pfizer offers a yield of 7.63% to investors and pays a quarterly dividend of $0.43 per share. Haleon PLC pays 39.53% of its earnings as a dividend. Pfizer pays out 118.44% of its earnings as a dividend. Haleon PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Pfizer's is not.
-
Which has Better Financial Ratios HLN or PFE?
Haleon PLC quarterly revenues are $3.5B, which are smaller than Pfizer quarterly revenues of $13.7B. Haleon PLC's net income of $295.8M is lower than Pfizer's net income of $3B. Notably, Haleon PLC's price-to-earnings ratio is 26.69x while Pfizer's PE ratio is 16.14x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Haleon PLC is 3.43x versus 2.03x for Pfizer. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HLNHaleon PLC3.43x 26.69x $3.5B $295.8M PFEPfizer2.03x 16.14x $13.7B $3B
-
Which has Higher Returns HLN or SNN?
Smith & Nephew PLC has a net margin of 8.37% compared to Haleon PLC's net margin of --. Haleon PLC's return on equity of 8.91% beat Smith & Nephew PLC's return on equity of 7.88%.
Company Gross Margin Earnings Per Share Invested Capital HLNHaleon PLC55.38% $0.06 $32.9B SNNSmith & Nephew PLC-- -- $8.4B -
What do Analysts Say About HLN or SNN?
Haleon PLC has a consensus price target of $11.13, signalling upside risk potential of 3.66%. On the other hand Smith & Nephew PLC has an analysts' consensus of $32.84 which suggests that it could grow by 15.89%. Given that Smith & Nephew PLC has higher upside potential than Haleon PLC, analysts believe Smith & Nephew PLC is more attractive than Haleon PLC.
Company Buy Ratings Hold Ratings Sell Ratings HLNHaleon PLC2 1 0 SNNSmith & Nephew PLC1 2 0 -
Is HLN or SNN More Risky?
Haleon PLC has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Smith & Nephew PLC has a beta of 0.678, suggesting its less volatile than the S&P 500 by 32.176%.
-
Which is a Better Dividend Stock HLN or SNN?
Haleon PLC has a quarterly dividend of $0.12 per share corresponding to a yield of 1.58%. Smith & Nephew PLC offers a yield of 2.65% to investors and pays a quarterly dividend of $0.46 per share. Haleon PLC pays 39.53% of its earnings as a dividend. Smith & Nephew PLC pays out 79.37% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios HLN or SNN?
Haleon PLC quarterly revenues are $3.5B, which are larger than Smith & Nephew PLC quarterly revenues of --. Haleon PLC's net income of $295.8M is higher than Smith & Nephew PLC's net income of --. Notably, Haleon PLC's price-to-earnings ratio is 26.69x while Smith & Nephew PLC's PE ratio is 30.15x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Haleon PLC is 3.43x versus 2.14x for Smith & Nephew PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HLNHaleon PLC3.43x 26.69x $3.5B $295.8M SNNSmith & Nephew PLC2.14x 30.15x -- --
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Butterfly Network the Best Small-Cap Stock?
Brought to public trading by an SPAC merger in early…
Is Spotify a Millionaire-Maker Stock?
Spotify (NYSE:SPOT) may seem like an expensive proposition trading closer…
Stock Ideas
Buy
68
Is MSFT Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 37x
Sell
39
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Buy
61
Is NVDA Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 40x
Alerts
Buy
60
RGC alert for May 10
Regencell Bioscience Holdings [RGC] is up 79.25% over the past day.
Buy
97
NGVC alert for May 10
Natural Grocers by Vitamin Cottage [NGVC] is up 30.26% over the past day.
Sell
38
ONTO alert for May 10
Onto Innovation [ONTO] is down 30.17% over the past day.
